PD-L1/IDO Peptide Vaccine + Pembrolizumab
Phase 1RecruitingDevelopment Stage
High Risk Non-Muscle Invasive Bladder Urothelial Carcinoma
High Risk Non-Muscle Invasive Bladder Urothelial Carcinoma, Stage 0a Bladder Cancer AJCC v8, Stage 0is Bladder Cancer AJCC v8, Stage I Bladder Cancer AJCC v8
Apr 19, 2023 → Dec 1, 2026
About PD-L1/IDO Peptide Vaccine + Pembrolizumab
PD-L1/IDO Peptide Vaccine + Pembrolizumab is a phase 1 stage product being developed by IO Biotech for High Risk Non-Muscle Invasive Bladder Urothelial Carcinoma. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05843448. Target conditions include High Risk Non-Muscle Invasive Bladder Urothelial Carcinoma, Stage 0a Bladder Cancer AJCC v8, Stage 0is Bladder Cancer AJCC v8.
Hype Score Breakdown
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05843448 | Phase 1 | Recruiting |
Competing Products
20 competing products in High Risk Non-Muscle Invasive Bladder Urothelial Carcinoma